OncoMatch/Clinical Trials/NCT06732323
A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
Is NCT06732323 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including ESG401 and Investigator's Choice Chemotherapy for triple-negative breast cancer (tnbc).
Treatment: ESG401 · Investigator's Choice Chemotherapy — The aim of this study is to evaluate the efficacy and safety of ESG401 as first-line treatment in patients with unresectable recurrent or metastatic triple-negative breast cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Triple-Negative Breast Cancer
Breast Carcinoma
Biomarker criteria
Allowed: PD-L1 (CD274) negative
Participants whose tumours are PD-L1-negative
Allowed: PD-L1 (CD274) positive
Participants whose tumours are PD-L1-positive and have relapsed after prior PD-1/PD-L1 inhibitor therapy for early-stage breast cancer, or comorbidities precluding PD-1/PD-L1 inhibitor therapy
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic anti-cancer therapy
Exception: for unresectable recurrent or metastatic disease
No prior systemic anti-cancer therapy for unresectable recurrent or metastatic disease
Cannot have received: topoisomerase I inhibitor
Prior topoisomerase I inhibitor therapy, including antibody-drug conjugate(ADC) therapy
Cannot have received: antibody-drug conjugate
Prior topoisomerase I inhibitor therapy, including antibody-drug conjugate(ADC) therapy
Cannot have received: TROP2 targeted therapy
prior TROP2 targeted therapy
Lab requirements
Blood counts
adequate organ and bone marrow function
Kidney function
adequate organ and bone marrow function
Liver function
adequate organ and bone marrow function
Adequate organ and bone marrow function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify